United States Patent 8,637,451 Scope, Claims, and Patent Landscape for GCGR/Guanylate Cyclase Receptor Agonist Peptide SEQ ID NO:20
Patent 8,637,451 claims a narrow method-of-treatment use case built around one specific peptide sequence (SEQ ID NO:20), a specific peptide conformational constraint ((4,12; 7,15) bicycle), and a defined pharmacodynamic target (inducing cGMP production in gastrointestinal epithelial cells). Dependent claim coverage adds a cGMP-potentiation combination using cGMP-dependent phosphodiesterase inhibition (with specified inhibitors) and a limited dosage-form position (powder formulation).
Practical takeaways: enforceability and infringement exposure hinge on whether a challenger (i) uses the same peptide identity and bicycled topology, (ii) administers it to stimulate water transport specifically in the gastrointestinal tract via cGMP generation in GI epithelial cells, and (iii) uses the same claimed combination levers (sulindac sulfone, zaprinast, or motapizone) and/or the “powder” formulation if relying on dependent claims.
What does US Drug Patent 8,637,451 claim, and how broad is the method-of-use coverage?
Claim 1 is the independent claim and it is structured as a method in a patient. The claim scope is driven by three hard limitations:
- Active identity: a guanylate cyclase receptor agonist peptide consisting of SEQ ID NO:20.
- Conformational constraint: the peptide is (4,12; 7,15) bicycle.
- Mechanistic effect and anatomical target: administration is in an amount sufficient to induce cGMP production in a gastrointestinal epithelial cell, to stimulate water transport in the gastrointestinal tract.
Claim breadth analysis (coverage envelope):
- “Consisting of SEQ ID NO:20” is restrictive. Any peptide with modifications that changes sequence content outside what the patentee counts as SEQ ID NO:20 is outside claim 1’s literal peptide identity.
- The bicycling constraint is also restrictive. Even if a competitor uses a “same sequence” peptide, different cyclization pairing or topology would likely avoid the literal (4,12; 7,15) bicycle limitation.
- Mechanistic target (“induce cGMP production in a gastrointestinal epithelial cell”) narrows infringement arguments because the accused product must be able to elicit the claimed cGMP response in GI epithelial cells as part of the asserted method.
- Method framing (“stimulating water transport”) reduces claim scope versus a purely pharmacodynamic claim. The method must be directed to GI water transport outcomes, which tends to align with secretagogue-like mechanisms and GI indications.
Claim 1 practical infringement trigger
A party is at highest risk if it administers:
- the exact peptide identity (SEQ ID NO:20),
- with the exact bicycling geometry ((4,12; 7,15)),
- to a patient to drive GI epithelial cGMP, with the intended or expected physiological result being increased water transport in the GI tract.
How strong is claim 1 if a generic or biosimilar-style “same target” substitute is used?
US 8,637,451 is not a “class claim” by drug target alone. It is a “sequence + constrained topology + GI-cGMP effect” method claim. That structure tends to strengthen validity/infringement positions for the patentee against:
- peptides in the same general pathway but with different sequences,
- bicycled variants with different ring constraints,
- non-peptide agonists of soluble or particulate guanylate cyclase that induce cGMP through other activation modes.
Key strength vectors:
- Sequence restriction: “consisting of SEQ ID NO:20.”
- Topology restriction: “(4,12; 7,15) bicycle.”
- Target tissue mechanistic narrowing: “GI epithelial cell cGMP production.”
Key weakness vectors (for the patentee to anticipate):
- If the accused product uses a peptide that differs in sequence identity or bicycling pairings, a challenger can argue non-infringement.
- If the accused product induces cGMP in another cell population, or cGMP generation is not attributable to the administered peptide in the GI epithelial cell context for the method being practiced, the patentee’s “amount sufficient to induce cGMP production in a gastrointestinal epithelial cell” element becomes a factual battleground.
What does dependent claim 2 add: PDE5? cGMP-dependent PDE inhibitors, and what’s the combination coverage?
Claim 2 adds a second therapeutic step layered on top of claim 1:
- “Further comprising administering… an effective dose of an inhibitor of cGMP-dependent phosphodiesterase”
- The inhibitor is selected from:
- sulindac sulfone
- zaprinast
- motapizone
- Administration can be concurrently or sequentially with the peptide.
Claim 2 scope consequences
- The combination claim is narrow in that it is limited to three named inhibitors.
- It is broad in timing: concurrent or sequential administration both sit inside the claim.
- It is still method-of-use anchored to claim 1’s peptide and GI epithelial cGMP effect, meaning claim 2 is unlikely to read on a regimen that uses those PDE inhibitors with a different peptide sequence or topology.
Infringement risk profile for claim 2:
- High risk when an accused regimen uses any of the three listed inhibitors in a way that is intended to inhibit cGMP-dependent PDE and the regimen also includes the claim 1 peptide/bicycle to induce GI epithelial cGMP and water transport.
- Lower risk if a challenger substitutes a different PDE inhibitor not listed, even if it inhibits cGMP-dependent PDE.
What does dependent claim 3 cover: “formulated as a powder” and how does formulation affect enforcement?
Claim 3 states: “The method of claim 1, wherein said peptide is formulated as a powder.”
Formulation claim implications
- Claim 3 is dependent, so it inherits all claim 1 elements and only adds the “powder formulation” limitation.
- This is a narrower carve-out that can be avoided if the accused regimen uses:
- a liquid/solution form,
- a reconstitutable liquid kit that is administered as a solution,
- a non-powder delivery system (capsule with dissolved peptide, etc.), depending on how “powder” is construed in the patent and prosecution history.
Enforcement reality
In practice, formulation dependent claims can become leverage points for infringement and licensing negotiations because formulation is often easier to change than active sequence. That said, if the accused product is delivered as a powder (dry powder, lyophilized cake treated as powder upon reconstitution, or similar), claim 3 can add value.
What patents likely matter around US 8,637,451: peptide identity, bicycling topology, and GI cGMP water transport methods?
This analysis is constrained to the information contained in the provided claim text. It is not possible to reliably enumerate the full US and family-wide patent estate (publication numbers, assignees, expiration dates, and claim charts) for US 8,637,451 without additional bibliographic data, prosecution record, and legal status documents.
What can be concluded from claim structure alone is the likely landscape segmentation that competitors and litigators will focus on:
1) Peptide-defining IP (sequence and topology)
- Patents in this cluster typically claim:
- specific peptide sequences and analogs,
- specific cyclization constraints (here, the (4,12; 7,15) bicycle),
- methods of making bicycled peptides.
Why it matters: if the core identity is protected, it blocks “design-around” attempts that keep the same pharmacology but alter cyclization patterns or sequence boundaries.
2) Mechanism and method-of-use IP
- Patents typically claim:
- GI-targeted cGMP induction,
- stimulation of water transport or secretory/absorptive balance changes in GI tissue,
- patient selection and dosing regimens.
Why it matters: claim 1 is a method-of-use. If competitors target the same clinical outcome with the same mechanistic endpoint, they raise infringement risk even with different device/delivery details (as long as the peptide identity and topology are maintained).
3) Combination and potentiation IP
- Claim 2 implies an IP cluster around:
- cGMP-dependent PDE inhibition,
- named inhibitor options (sulindac sulfone, zaprinast, motapizone),
- concurrent/sequential dosing logic.
Why it matters: combination exclusivity often determines settlement scope in paragraph IV or licensing disputes.
4) Dosage form IP (powder)
- Claim 3 targets a particular formulation position.
- Competitors often pursue dosage-form workarounds to avoid dependent claims, assuming the independent claim can still be avoided.
How does the “consisting of SEQ ID NO:20” and “(4,12; 7,15) bicycle” limit design-around options?
Design-around option count is low if a competitor must still:
- use the same sequence,
- and use the same bicycling constraint pairing.
Common design-around strategies that would likely fall outside claim 1:
- altering cyclization residue pairing (different bicycle topology),
- substituting a different amino acid sequence that is not literally “SEQ ID NO:20,”
- using a non-peptide guanylate cyclase agonist that induces cGMP without using the claimed peptide,
- targeting cGMP in different tissue types rather than GI epithelial cells in the claimed method context.
Practical consequence: claim 1 protects a specific “molecule + conformation + GI epithelial cGMP effect” combination. Competitors can still seek:
- different delivery format not affecting peptide identity,
- different clinical endpoints not framed as “stimulating water transport,”
but those arguments are weaker if the clinical effect is the same.
How do claim 2’s named PDE inhibitors affect competitive strategy and licensing leverage?
Claim 2 is a combination with three named inhibitors. This can drive two strategic realities:
- If a competing program uses one of the named inhibitors, it increases the chance of capturing dependent claim 2 if it also uses SEQ ID NO:20 bicycle peptide for GI epithelial cGMP induction.
- If a competing program avoids all three, it may reduce literal claim 2 infringement but not necessarily claim 1.
Because claim 2 is limited to named inhibitors, the key competitive question becomes whether competitors can substitute other PDE inhibitors. The more substitution is possible in development, the less leverage claim 2 provides.
What do the claims imply about likely FDA regulatory classification and what Orange Book status would be expected?
The claim text describes a peptide administered to patients. The legal status in the Orange Book and the pathway classification (NDA vs 505(b)(2), etc.) cannot be determined from claims alone.
What matters for landscape mapping:
- If the product is an NDA-listed peptide drug substance, it would typically appear in the Orange Book with patent listings that track formulation, method-of-use, and composition claims.
- If the peptide is not small molecule and is developed as a biologic, it could instead sit in the BLA/biologics framework, where patent listing practices differ.
Given only the claim text, the specific Orange Book entry cannot be identified here.
What generic entry risks exist for claim 1: method patents vs product patents?
Claim 1 is a method-of-use claim. That generally means generic entry risk depends on whether the generic product is used in an infringing manner.
For a challenger, risk increases if:
- they cannot avoid the use method because they market a product whose labeling or intended use matches the claimed GI water transport stimulation via GI epithelial cGMP,
- the clinical practice around the drug is aligned with the claim.
Risk decreases if:
- the generic product’s label does not cover the claimed method, and the generic launch is designed to avoid instructing or inducing the infringing method,
- the challenger uses a non-literal variant (different sequence or bicycle topology) outside claim 1.
Key takeaways
- Claim 1 scope is molecule-specific and conformation-specific: SEQ ID NO:20 plus the exact (4,12; 7,15) bicycle plus a GI epithelial cGMP induction effect tied to stimulation of water transport.
- Dependent claim 2 adds a narrow named combination: PDE inhibitors restricted to sulindac sulfone, zaprinast, or motapizone, administered concurrently or sequentially.
- Dependent claim 3 is dosage-form narrow: only powder formulation is covered.
- Design-around is possible mainly by changing peptide identity/topology; altering delivery format may not avoid claim 1 if the same peptide and effect are used.
- Competitive leverage concentrates on whether challengers can avoid SEQ ID NO:20 and (4,12; 7,15) bicycle, or whether they can avoid the specific PDE inhibitors and powder formulation.
FAQs
1) If a competitor uses the same peptide sequence but a different bicycle topology, is claim 1 avoided?
Yes, because claim 1 requires the peptide to be specifically the (4,12; 7,15) bicycle.
2) Does claim 2 cover PDE inhibitors other than sulindac sulfone, zaprinast, and motapizone?
No. Claim 2 is restricted to inhibitors selected from those three compounds.
3) Can a product avoid claim 3 by switching from powder to liquid?
Yes in principle, because claim 3 is limited to a powder formulation.
4) What is the likely practical test for infringement of claim 1?
Whether the administered regimen uses a peptide that meets SEQ ID NO:20 identity, the (4,12; 7,15) bicycle topology, and induces cGMP production in GI epithelial cells to stimulate GI water transport.
5) Does claim 1 require the inhibitor step in claim 2 to be present?
No. Claim 1 stands alone; claim 2 adds the PDE inhibitor combination.
References
None.
